Granules net rises 6% on higher revenue

August 09, 2022 08:38 pm | Updated 08:38 pm IST - HYDERABAD

Drugmaker Granules India reported consolidated net profit increased 6% to ₹128 crore in the quarter ended June even as growth across all geographies and segments pushed up revenue from operations 20% to ₹1,020 crore.

U.S. pricing pressure as well as increased cost of raw materials, solvents and logistics remain challenges, CMD Krishna Prasad Chigurupati said. Active pharmaceuticals ingredients (API), pharmaceutical formulation intermediates and finished dosages accounted for 23%, 23% and 54% of revenue respectively.

“While overall geopolitical environment is far from being normal, we must take these in our stride and execute Granules 2.0 strategy without any flaw. I feel confident when I see the transformation taking place... [and] we continue to grow and demonstrate excellence and differentiation in whatever we do,” he said.

In a release on the Q1 performance, Granules said it had acquired capital assets of a small biotech company to gain ready platform for biotechnology focused research and manufacturing. The company had also received approval from the Centre’s Department of Pharmaceuticals under the Production Linked Incentive scheme to manufacture Dicyandiamide (DCDA).

Buyback approved

The company has approved a buyback of 62.50 lakh equity shares (face value of ₹1) at a price of ₹400 each for an aggregate maximum amount of ₹250 crore.

The Board has fixed August 23, 2022 as the record date for determining the entitlement and names of equity shareholders eligible to participate in the buyback.

Top News Today

Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.